technology

Press Releases

Press Releases

 
Press Releases
Date Title and Summary View
Jun 11, 2014 BOTHELL, Wash., June 11, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc., ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing therapeutic antibodies for the treatment of migraine, autoimmune and inflammatory diseases, today announced that members of Alder's senior management team will present at two upcoming confe...
Jun 18, 2014 BOTHELL, Wash., June 18, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today provided recent corporate highlights and reported its financial results for the fi...
Jun 26, 2014 BOTHELL, Wash., June 26, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced Peter J. Goadsby, M.D., Ph.D., director, NIHR-Wellcome Trust Clinical Re...
Jun 27, 2014 BOTHELL, Wash., June 27, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc., ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced that Alder will be added to the Russell 3000® Index at the close o...
Jul 29, 2014 BOTHELL, Wash., July 29, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced that it will report its second quarter 2014 financial and operating resu...
Aug 5, 2014 BOTHELL, Wash., Aug. 5, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today provided recent corporate highlights and reported its financial results for the sec...
Sep 2, 2014 Company Plans to Continue Development of Therapeutic Antibody for Autoimmune/Inflammatory DiseaseConference Call/Webcast Scheduled for 9 a.m. EDT Today BOTHELL, Wash., Sept. 2, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a clinical-stage company developing antibody therapeutics, today announced that it has regained th...
Oct 6, 2014 BOTHELL, Wash., Oct. 6, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals Inc. (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing antibody therapeutics, today announced data from the proof-of-concept clinical trial of ALD403 published in the October 6, 2014 issue of Lancet Neurology demonstrates that ALD403 met the primary study e...
Oct 24, 2014 BOTHELL, Wash., Oct. 24, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. ("Alder") (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced that it will report its third quarter 2014 financial and operating resul...
Nov 3, 2014 BOTHELL, Wash., Nov. 3, 2014 (GLOBE NEWSWIRE) -- Alder BioPharmaceuticals, Inc. (Nasdaq:ALDR), a clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for the treatment of migraine, autoimmune and inflammatory diseases, today announced the initiation of a Phase 2b clinical trial of ALD403, its antibody therapeutic can...
Page:
1
... NextLast
= add release to Briefcase